Swiss stocks – Factors to watch on March 29

ZURICH, March 29 (Reuters) – Swiss stocks are seen opening
little changed on Monday as Middle East unrest, Europe’s debt
crisis and Japan’s nuclear emergency keeps investors wary ahead
of the closing of the first quarter.

The Swiss blue-chip index SMI (.SSMI: Quote, Profile, Research) was indicated to open
down 6 points at 6,355 points, premarket data provided by bank
Clariden Leu showed. (CLPRE: Quote, Profile, Research)

The following are some of the main factors expected to
affect Swiss stocks on Tuesday:

CREDIT SUISSE (CSGN.VX: Quote, Profile, Research)

A U.S. investigation into Credit Suisse (CSGN.VX: Quote, Profile, Research) bankers
for allegedly helping Americans dodge taxes is unlikely to be
extended to the bank as a whole, the U.S. ambassador to Bern was
quoted as saying on Tuesday.

For related news, click on [CSGN.VX]

UBS (UBSN.VX: Quote, Profile, Research) (UBS.N: Quote, Profile, Research)

Switzerland’s largest bank in terms of market value has
appointed mergers & acquisitions veteran Cary Kochman and Liam
Beere, head of EMEA M&A as joint global heads of M&A, according
to an internal memo seen by Reuters.

For related news, click on [UBSN.VX]

WEATHERFORD (WFT.VX: Quote, Profile, Research)(WFT.S: Quote, Profile, Research)

The oilfield products and services company CEO said he
expected North American margins to test prior highs of 30
percent, though he did not give a timeframe for the improvement.

For related news, click on [WFT.VX]

TRANSOCEAN (RIG.N: Quote, Profile, Research) (RIGN.VX: Quote, Profile, Research)

The world’s largest offshore drilling contractor will
consider spinning off an older part of its fleet in order to
improve its profile, its chief executive said on Monday.

For related news, click on [RIGN.VX]

ECONOMY [M-CH]

* The UBS Swiss consumption indicator fell to 1.46 in
February from a revised 1.66 in January, the Swiss bank’s
economists said.

COMPANY STATEMENTS [CNR-CH]

* Lonza (LONN.VX: Quote, Profile, Research) announced 16 million pounds ($25.6
million) investment to further its Slough, UK biopharmaceutical
manufacturing facility and strengthen its global network of
biologics development and manufacturing.

EQUITY RESEARCH [CH-RCH]

For companies trading ex-dividend, please click on:

(.EX.S: Quote, Profile, Research) for all Swiss stocks

(.EXSMI.S: Quote, Profile, Research) for blue chips

(.EXNSMI.S: Quote, Profile, Research) for other stocks

Swiss stocks – Factors to watch on March 29